Eligible patients ( newly diagnosed , histologically proven supratentorial glioblastoma , methylated MGMT promoter , and age @ years ) were stratified for prognostic Radiation Therapy Oncology Group recursive partitioning analysis class and geographic region and centrally randomised in a @:@ ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide @ mg intravenously twice weekly ( cilengitide group ) or temozolomide chemoradiotherapy alone ( control group ) .